A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Active, not recruiting · Phase 1 · NCT06606106
Conditions: Overweight, Obesity
At a glance
- Research payments reported, 2025
- $27.2M
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 302
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3537031 (drug), Placebo (drug)
- Dates
- Started 2024-09-05; completion 2026-11
- Results posted
- Not yet
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body weight will be measured. The study will last approximately 49 weeks excluding a screening period.
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $27.2M in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Steven H. Reynolds, D.O. Family Medicine · Long Beach, CA
- Hugh A. Coleman, DO Family Medicine · Daytona Beach, FL
- William J. Howitt, MD Family Medicine · Springfield, MO
- Alexander N. Prezioso, M.D. Specialist · Lake Hopatcong, NJ
- Abiodun Adefurin, MD Hospitalist · Nashville, TN
- Archie V. Bowie II, MD Student in an Organized Health Care Education/Training Program · Odessa, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $7.6M
- Covance Clinical Research LP Dallas $7.6M
- Erg Holding Co LLC DBA St Louis Clinical Trials LLC $5.8M
- Collaborative Neuroscience Research LLC $4.8M
- Bio Kinetic Clinical Applications LLC $1.3M
- Clinical Pharmacology of Miami Inc $48,138
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.